Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized intra-individual study with the sirolimus coated cypher select(TM) and the paclitaxel(TM) coated express balloon expandable stents for the treatment of patients with two de novo native coronary artery lesions.

Trial Profile

A prospective, randomized intra-individual study with the sirolimus coated cypher select(TM) and the paclitaxel(TM) coated express balloon expandable stents for the treatment of patients with two de novo native coronary artery lesions.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Paclitaxel
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms FRE-RACE
  • Most Recent Events

    • 20 May 2009 Planned number of patients changed from 110 to 112, additional lead trial centre University Hospital Freiburg and lead trial investigator Manfred Zehender as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials. gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top